Despite initial interest in targeting FAP for cancer treatment, a phase II exploratory trial of monoclonal antibody sibrotuzumab targeting FAP in metastatic colorectal cancer was discontinued early as it did not show efficacy (58). Here, FAP is linked to cancer.